Phillip D Zamore PhD

Research Focus - Small RNA Silencing Pathways

Representative Publications

• Terminal modification, sequence, length, and PIWI-protein identity determine piRNA stability. Gainetdinov I, Colpan C, Cecchini K, Arif A, Jouravleva K, Albosta P, Vega-Badillo J, Lee Y, Özata DM, Zamore PD.Mol Cell. 2021 Sep 29:S1097-2765(21)00746-2. doi: 10.1016/j.molcel.2021.09.012. Online ahead of print.PMID: 34626567 Read Publication

In the News

• 

  Sep 16, 2024

  UMass Chan Early Independence Fellows program aims to develop future top investigators

  Two new donor-funded fellowships are being launched this year at UMass Chan to recruit recent postdoctoral scientists and, through intensive mentoring and resource support, foster their development as independent investigators. The fellowships align with the vision embodied in The Morningside Foundation’s transformational $175 million gift in 2021.  

  Read more

  , Graduate School of Biomedical Sciences, School of Medicine, Medicine, Faculty, Fellow, Research, Terence Flotte, Katherine Fitzgerald, Brian Lewis, Molecular, Cell and Cancer Biology, Population and Quantitative Health Sciences, RNA Therapeutics Institute, Phillip Zamore, Latest News, Top Stories,
• 

  Oct 9, 2023

  Phillip Zamore, Roger Davis elected to National Academy of Medicine

  UMass Chan Medical School scientists Phillip D. Zamore, PhD, and Roger J. Davis, PhD, FRS, were elected to the National Academy of Medicine on Oct. 9 for their distinguished contributions to medicine and health.

  Read more

  , School of Medicine, Cancer Center, Faculty, Award, Research, Roger J. Davis, RNA Therapeutics Institute, Phillip Zamore, Program in Molecular Medicine, Latest News, Top Stories,
• 

  May 5, 2023

  Phillip Zamore elected to National Academy of Sciences

  Phillip D. Zamore, PhD, is one of 120 newly elected members of the National Academy of Sciences who were recognized for distinguished achievements in original research. Dr. Zamore is credited with identifying the biochemical machinery responsible for RNA silencing.

  Read more

  , Graduate School of Biomedical Sciences, School of Medicine, Cancer Center, Faculty, Award, Research, Interdisciplinary, MD/PhD, RNA Therapeutics Institute, Phillip Zamore, Bioinformatics and Integrative Biology, Latest News, Biochemistry and Molecular Biotechnology, Zamore Lab, Top Stories,
• 

  Apr 24, 2023

  Katherine Fitzgerald, Phillip Zamore elected to American Academy of Arts & Sciences

  Katherine Fitzgerald, PhD, and Phillip D. Zamore, PhD, were elected to the American Academy of Arts & Sciences, which honors excellence and leaders from every field of human endeavor to examine new ideas, address issues of importance to the nation and the world, and work together to cultivate every art and science.

  Read more

  , Graduate School of Biomedical Sciences, School of Medicine, Medicine, Cancer Center, Faculty, Research, Katherine Fitzgerald, RNA Therapeutics Institute, Phillip Zamore, Latest News, Program in Innate Immunity, Top Stories, For the Press,
• 

  Dec 18, 2020

  Inside the new mRNA vaccines for COVID-19

  The new vaccines by Pfizer/BioNTech and Moderna use messenger RNA to stimulate the immune system to protect against COVID-19. These vaccines are the first of their kind and researchers at UMass Medical School are among the leading RNA biologists in the world.

  Read more

  , Graduate School of Biomedical Sciences, School of Medicine, Office of Advancement, Faculty, Craig C. Mello, Anastasia Khvorova, Jonathan K. Watts, Novel Coronavirus, Biochemistry and Molecular Biotechnology, RNA Therapeutics Institute, Ambros Lab, Phillip Zamore, Program in Molecular Medicine,